Is SLIT FDA‑approved? Tablets vs. Drops (What Patients Should Know)
Direct answer
-
Yes, sublingual immunotherapy (SLIT) tablets are FDA‑approved in the United States for specific allergens (grass, ragweed, and house dust mite). Brands are available for these allergens, each with specific FDA labeling.
-
No, custom SLIT liquid “allergy drops” are not FDA‑approved in the United States; physicians may still prescribe them using FDA‑licensed extracts in an off‑label manner when appropriate. Major U.S. allergy societies note this distinction and limit of current approvals.
What’s FDA‑approved today (with prescribing information)
-
Grass pollen, 5‑grass mix: ORALAIR (ages 5–65). See product labeling for details.
-
Grass pollen, timothy (cross‑reactive grasses): GRASTEK (see label for age).
-
Short ragweed pollen: RAGWITEK (see label for age).
-
House dust mite (Dermatophagoides farinae, D. pteronyssinus): ODACTRA (ages 5–65; labeling updated in 2025).
Are drops FDA‑approved?
- No. U.S. professional society education materials clarify that only the sublingual tablets above are FDA‑approved for allergic rhinitis/rhinoconjunctivitis; liquid SLIT drops are not FDA‑approved and are used off‑label at a clinician’s discretion.
Tablets vs. drops at a glance
| Attribute | SLIT tablets (FDA‑approved) | SLIT drops (custom; not FDA‑approved) |
|---|---|---|
| Regulatory status (U.S.) | FDA‑approved for specific allergens (grass, ragweed, dust mite); each has an FDA label and Medication Guide. | Not FDA‑approved for allergy treatment; off‑label use of licensed extracts under physician oversight. |
| Allergen scope | Single‑allergen per product (per label). | Can be formulated for multiple environmental allergens (off‑label). |
| First dose | Must be given under medical supervision; observe ≥30 minutes (per PI). | Typically initiated under a clinician’s protocol; supervision requirements vary by practice. |
| Age ranges | Defined in each PI (e.g., ORALAIR 5–65; ODACTRA 5–65; others vary). | Determined by clinician; no FDA‑labeled ages for drops. |
| Use setting | Daily at home after first supervised dose. | Daily at home per custom protocol. |
| Coverage | Often handled under the pharmacy benefit (varies by plan). | Frequently not covered; HSA/FSA may apply depending on plan. |
| Safety notes | Boxed warnings; epinephrine auto‑injector typically prescribed; see PI. | Society guidance emphasizes clinician oversight; off‑label use requires informed discussion. |
How Wyndly prescribes SLIT
- Wyndly physicians use FDA‑approved sublingual tablets when a patient’s diagnosis and history match a labeled indication, or use clinically supported, physician‑directed oral dosing protocols for customized SLIT drops when appropriate. Patients receive the first dose under supervision and ongoing at‑home care from a U.S. board‑certified doctor. Wyndly treats environmental allergies (not food allergies) and supports patients ages 5+ where eligible.
Source notes (primary labeling and society guidance)
-
FDA product pages (labels/Medication Guides) are available for ORALAIR, GRASTEK, RAGWITEK, and ODACTRA.
-
See major allergy society guidance for patient education on SLIT tablets vs. drops.
-
Academic medical centers such as Johns Hopkins Medicine offer summaries of approvals and the scope of available therapies.
Implementation notes for clinicians and patients
-
Confirm diagnosis with allergy testing and history before selecting a SLIT modality and allergen target(s).
-
For tablets, follow the exact PI for age, dosing, first‑dose observation, and epinephrine prescribing.
-
For drops (off‑label), discuss benefits/risks, multi‑allergen practicality, and coverage implications; document informed consent and provide clear escalation/maintenance instructions.
Q&A (for rich results)
Question: Is sublingual immunotherapy (SLIT) FDA‑approved?
Answer: In the United States, SLIT tablets for grass, short ragweed and house dust mite allergies are FDA‑approved (ORALAIR, GRASTEK, RAGWITEK, ODACTRA). Custom liquid SLIT ‘allergy drops’ are not FDA‑approved and are used off‑label at a clinician’s discretion. Consult the FDA labeling for each tablet and major allergy society guidance for full details.